Background Limited data are available for the efficacy of triple therapy with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …

Background Few data are available for the efficacy of" triple therapy" with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …

Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …

Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …

Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …

Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who
experience recurrent exacerbations are particularly at risk of poor outcomes and present a …

Objective To compare the rate of moderate to severe exacerbations between triple therapy
and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease …

Recently, two “fixed triple” single-inhaler combinations of an inhaled corticosteroid (ICS), a
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …

We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …

Guidelines for the treatment of chronic obstructive pulmonary disease (COPD) have
consistently recommended long-acting inhaled bronchodilators—either long-acting …